Gene-editing therapy aimed at two targets - HIV-1, the virus that causes AIDS, and CCR5, the co-receptor that helps the virus get into cells - can effectively eliminate HIV infection, new research from the Lewis Katz School of Medicine at Temple University and the University of Nebraska Medical Center (UNMC) shows. The study, published online in the journal The Proceedings of the National Academy of Sciences (PNAS), is the first to combine a dual gene-editing strategy with antiretroviral drugs to cure animals of HIV-1.

A new approach to the genetic engineering of cells promises significant improvements in speed, efficiency, and reduction in cellular toxicity compared to current methods. The approach could also power the development of advanced cell therapies for cancers and other diseases, according to a study from researchers in the Perelman School of Medicine at the University of Pennsylvania.

19 - 20 June 2023, London, UK.
SAE Media Group is proud to announce the inaugural Cell and Gene Therapy Conference. As part of SAE Media Group's leading series of drug discovery conferences, this year's event will bring together expertise from individuals across the advanced therapeutics community. The two-day conference will offer a series of presentations, through which delegates will gain insight into the latest developments in discovery, development and delivery of cell and gene therapies.

The University of Cincinnati's Soma Sengupta, MD, PhD, published an article in the Journal of Neuro-Oncology April 25 discussing her journey and approach to practicing integrative neuro-oncology.

Sengupta, associate professor in neurology, director of neuro-oncology clinical trials, associate director of the Brain Tumor Center and a UC Health neuro-oncologist,

A new class of immunotherapy shows promising results for fighting the most aggressive form of skin cancer.

The study, published today in Nature Communications by researchers from King's College London and Guy’s and St Thomas’ NHS Foundation Trust, investigates whether a novel antibody can target and treat melanomas.

Targeting part of an antiviral pathway triggered by the accumulation of a key pathogen shared in Alzheimer's disease and frontotemporal dementia may one day offer a new therapeutic approach to deterring or delaying cognitive decline, according to preclinical research led by Weill Cornell Medicine scientists.

Multiple sclerosis (MS) is a devastating autoimmune disease that destroys the protective myelin covering around nerves, disrupting communication between the brain and body, and causing patients' ability to move and function to progressively decline. The Atlas of MS reported in 2020 that someone is diagnosed with MS every five minutes around the world, adding to about 2.8 million individuals that currently have to live with the disease. Alarmingly, since 2013, the world-wide prevalence of MS has risen by 30%.